Discontinued — last reported Q2 '13
Vertex Pharmaceuticals Occupancy and equipment remained flat by 0.0% to $48.68M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 87.4%, from $25.98M to $48.68M. Over 2 years (FY 2023 to FY 2025), Occupancy and equipment shows an upward trend with a 101.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate expansion of the physical footprint or rising real estate costs, while a decrease suggests branch consolidation or a shift toward digital-first operations.
This metric represents the recurring costs associated with maintaining physical branch networks, corporate office space,...
Standard across all large financial institutions; peers often track this as a component of noninterest expense to measure operational leverage.
is_occupancy_and_equipment| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $47.80M | $103.90M | $194.70M |
| YoY Change | — | +117.4% | +87.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.